Premium
The Effect of Donepezil Treatment on Cardiovascular Mortality
Author(s) -
Sato K,
Urbano R,
Yu C,
Yamasaki F,
Sato T,
Jordan J,
Robertson D,
Diedrich A
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.98
Subject(s) - donepezil , medicine , hazard ratio , confidence interval , dementia , acetylcholinesterase , vascular dementia , clinical pharmacology , prospective cohort study , rivastigmine , clinical trial , pharmacology , disease , biochemistry , chemistry , enzyme
The acetylcholinesterase inhibitor donepezil hydrochloride improves cognitive function in patients with Alzheimer's disease and vascular dementia. Given acetylcholine's important actions on the heart, we undertook a retrospective cohort investigation to assess whether donepezil usage affects cardiovascular mortality. In patients treated with donepezil, hazard ratios for total and cardiovascular mortality were 0.68 ( P = 0.045, 95% confidence interval 0.46–0.99) and 0.54 ( P = 0.042, 95% confidence interval 0.30–0.98), respectively. The apparent survival benefit in donepezil‐treated patients should not be overinterpreted. Prospective clinical trials are warranted. Clinical Pharmacology & Therapeutics (2010) 88 3, 335–338. doi: 10.1038/clpt.2010.98